Unicycive Therapeutics (UNCY) Other Accumulated Expenses (2020 - 2026)

Unicycive Therapeutics has reported Other Accumulated Expenses for 7 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 103.57% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 103.57% YoY), and the FY2025 full-year result was $441000.0, up 11.93% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.7 million, up from $441000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $1.7 million in Q1 2026, with the low at $29000.0 in Q3 2024.
• Historically, Other Accumulated Expenses has averaged $432769.2 across 5 years, with a median of $394000.0 in 2024.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses plunged 94.21% — and 2025, when it surged 1300.0%.
• Unicycive Therapeutics' Other Accumulated Expenses stood at $522000.0 in 2022, then slumped by 45.79% to $283000.0 in 2023, then soared by 39.22% to $394000.0 in 2024, then climbed by 11.93% to $441000.0 in 2025, then soared by 274.83% to $1.7 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.7 million (Q1 2026), $441000.0 (Q4 2025), and $406000.0 (Q3 2025), per Business Quant data.